Company news

Anagenics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cellmids Evolis Patent to be Granted in China

February 3, 2020

Appendix 4C and Notes to Appendix 4C

January 29, 2020

Key Midkine Antibody Patents Granted in the US and Europe

January 5, 2020

Cellmid Reports on QVC Sales

December 5, 2019

Cellmid Signs Trading Agreement With API/Priceline

November 5, 2019

New TV Shopping Agreement for Evolis

October 13, 2019

New Evolis Distribution & Supply Agreements - China & Europe

October 1, 2019

FY2019 Financial Results

August 28, 2019

Patent for Improved Midkine Antibody Allowed in Europe

August 22, 2019

CDY Signs Distribution Agreement for EVOLIS in South Korea

August 5, 2019

Response to Appendix 4C Query

August 1, 2019

Cellmid Sets Another Sales Record in Q4 FY2019

July 4, 2019

Cellmids Evolis Registered in European Union (EU)

April 30, 2019

Minimum Holding Share Buy-Back

March 18, 2019

Appendix 4D, Half Year Accounts and Strategy Update

February 21, 2019

Significant New Findings Published on Midkine

February 7, 2019

Cellmid: Appendix 4C and Notes to Appendix 4C

January 22, 2019

Cellmid Expects Record Sales in Q2 FY2019

December 11, 2018

Cellmid Appoints Exclusive New Zealand Distributor

November 18, 2018

New Patents for Midkine Antibodies in USA and Europe

November 6, 2018

Ikon Legal Action - Decision

November 2, 2018

Cellmids Evolis Successfully Launched in USA stores

October 31, 2018

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

Lead Antibody Effective in Rare Chronic Kidney Disease

September 12, 2018

Cellmid Share Purchase Plan Completion

September 2, 2018

Evolis USA Distribution Update

August 30, 2018

Preliminary Final Report

August 24, 2018

Cleansing Notice and Appendix 3B

August 6, 2018

Cellmid Share Purchase Plan

July 31, 2018

Cellmid Share Placement Raises $9M

July 30, 2018

Cellmid updates on distribution of evolis

July 10, 2018

Cellmid to commence selling of evolis into Chinese market

May 2, 2018

Cellmid secures Bloomingdales USA partnership for evolis

April 23, 2018

Appendix 4C - quarterly

April 22, 2018

Cellmid signs distribution agreement for fillerina

April 4, 2018

Appendix 4D and Half Year Accounts

February 21, 2018

Record 2M sales for Cellmid FGF5 inhibitors

January 9, 2018

Cellmid quarterly operational update

January 8, 2018

Cellmid placement to strategic investor

December 15, 2017

Cellmid secures new US retail partner for evolis

December 6, 2017

Cellmid opens first concept store in tokyo

October 25, 2017

Proposed consolidation of securities

October 23, 2017

Cellmid receives $947K R&D tax credit

October 2, 2017

Cellmid completes US consumer study

August 20, 2017

Cellmid secures premium US retail channel for evolis

August 2, 2017

Nature Paper MK in Melanoma

July 3, 2017

Cellmids FGF5 inhibitor clinical study published

March 2, 2017

Cellmid to Refinance R&D Loan Facility

March 1, 2017

Cellmid: to Refinance R&D Loan Facility

February 28, 2017

Cellmid: Appendix 4D and Half Year Accounts

February 27, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 24 decks. Every deck is listed under its year.